Lyrica pregabalin: Phase III discontinued

Pfizer stopped the double-blind, international Phase III A0081244 trial to treat neuropathic pain associated with HIV neuropathy after a planned interim analysis of 246 patients by the study's DMC showed that improvements in neuropathic pain symptoms were "virtually identical" between the Lyrica and placebo groups. No safety concerns were identified. The trial planned to enroll 416 patients to receive twice-daily 75-300 mg Lyrica or placebo for about 19 weeks. ...